Replies to post #9092 on Todos Med Ltd (TOMDF)

[misiu143]

JoeForkeyBolo, I was just ready to post this , when I noticed you did it..
Good read..thank you.

GLTA longs.

[arpemd]

Thanks JFB, good article and discussion. Note this line:

If we learned anything from CytoDyn’s mishaps, it was that even 309 patients isn’t necessarily enough for an EUA.

and this one (which speaks of reg capture to me, considering the very sketchy approval of remdesivir): "The GILD, HGEN, TOMDF, and CYDY mortality data reconciles to real world conditions. The only thing that doesn’t make sense is: why the regulatory process wasn’t accelerated for any of the drugs besides Gilead’s on the announcement of such good data during a pandemic."

[Jorgeezzee]

Thank you for posting that link..Anytime a drug that has initial results that look good on the surface, the stock rallies hard..Just as was the case with VERU..

Now the light is being shined on the results, and it turns out that the results were NOT as good as first thought..and so, Todos gets another mention but, not on CNBC like VERU did..

Yes on articles and internet presentations all the results from trials and from people that use Tollovid, is positive..But none of it ends up on CNBC where it could really make a difference..Nevertheless, Todos churns along looking ever forward to it's day of recognition.

I did appreciate this part from the article...which tells me that Tollovir wins hands down in the race for a COVID Pill..

The best comparable to sabizabulin, however, is Tollovir™, manufactured by Todos Medical (OTCMKTS: TOMDF) which had a 100% reduction in mortality in severe to critical patients and reduced time of hospitalization and progression to a ventilator. For comparison purposes, the placebo group in leronlimab had a 24% mortality rate for severe to critical but they did not age stratify properly. The placebo group for Tollovid had a 22% mortality in severe to critical. In the active arm of Veru’s Sabizabulin phase 3 trial, the mortality rate was 20% for moderate-to-severe hospitalized COVID-19 patients

[Jorgeezzee]

This is also a part of the article that i wanted to share.


The safer bet in hospitalized COVID-19 is TOMDF and their Tollovir. They have been seeking an EUA in either Greece or Israel for the past couple of months after their clinical data showed a 100% reduction in mortality. At a $16 million market cap, an EUA could easily send the stock into the stratosphere to match VERU’s $800 million market cap. In their Phase 2 clinical trial Tollovir beat Gilead’s remdesivir and took dying off the table, but their study wasn’t powered high enough. Nor did they have the PR headlines that the trial was stopped early for efficacy even though it technically was. Investors may still take issue with the power of the study and unbelievably good results, but Tollovir targets the same biological target, the 3CL protease, as Pfizer’s (NYSE: PFE) drug Paxlovid, which displayed incredible efficacy in the outpatient setting, reducing hospitalizations and death by 89%. PFE’s 3CL inhibition is a proven Mechanism of Action (MOA) which makes TOMDF’s results very believable. The primary differences between the drugs are the safety due to Tollovir’s all natural composition versus Paxlovid’s small molecule chemical design. Tollovir also has an anti-inflammatory aspect in addition to its antiviral properties.